Top Page
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
(Sydney:RMD)
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD) vs. iShares MSCI Australia ETF (EWA)
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh Business Overview & Revenue Model
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh Earnings Call Summary
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.26B | 5.15B | 4.69B | 4.22B | 3.58B | 3.20B |
| Gross Profit | 3.16B | 3.05B | 2.66B | 2.36B | 2.02B | 1.84B |
| EBITDA | 1.87B | 1.92B | 1.53B | 1.36B | 1.18B | 1.10B |
| Net Income | 1.44B | 1.40B | 1.02B | 897.56M | 779.44M | 474.50M |
Balance Sheet | ||||||
| Total Assets | 8.31B | 8.17B | 6.87B | 6.75B | 5.10B | 4.73B |
| Cash, Cash Equivalents and Short-Term Investments | 1.38B | 1.21B | 238.36M | 227.89M | 273.71M | 295.28M |
| Total Debt | 846.35M | 851.81M | 899.21M | 1.58B | 917.55M | 793.72M |
| Total Liabilities | 2.19B | 2.21B | 2.01B | 2.62B | 1.74B | 1.84B |
| Stockholders Equity | 6.12B | 5.97B | 4.86B | 4.13B | 3.36B | 2.89B |
Cash Flow | ||||||
| Free Cash Flow | 1.76B | 1.65B | 1.29B | 559.30M | 195.11M | 619.89M |
| Operating Cash Flow | 1.88B | 1.75B | 1.40B | 693.30M | 351.15M | 736.72M |
| Investing Cash Flow | -254.77M | -200.04M | -269.78M | -1.16B | -229.92M | -158.46M |
| Financing Cash Flow | -685.77M | -606.25M | -1.12B | 422.87M | -128.36M | -764.63M |
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh Technical Analysis
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh Risk Analysis
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | AU$55.61B | 24.87 | 26.73% | 0.88% | 11.99% | 32.89% | |
69 Neutral | $27.86B | 241.69 | 50.70% | 0.21% | 31.88% | 39.10% | |
69 Neutral | $18.36B | 47.23 | 20.11% | 1.54% | 4.32% | 9.24% | |
64 Neutral | AU$10.27B | 19.43 | 6.32% | 4.59% | 9.44% | -0.37% | |
54 Neutral | $8.46B | 1,243.58 | 0.38% | 2.17% | 6.82% | -99.27% | |
53 Neutral | €35.60B | 61.26 | ― | 0.45% | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh Corporate Events
ResMed Inc.’s Chief Financial Officer, Brett Sandercock, reported a change in beneficial ownership of the company’s common stock. On November 3, 2025, Sandercock acquired 2,000 shares through stock options at a price of $101.64 per share and disposed of 3,000 shares at $247.54 per share. This transaction was conducted under a Rule 10b5-1 plan, indicating a pre-planned trading strategy. The change in ownership reflects ongoing management of equity holdings by the company’s executive, which may impact investor perceptions and the company’s stock performance.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$47.04 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
Resmed Inc announced a net decrease of 3,891,110 CHESS Depositary Interests (CDIs) issued over quoted securities for October 2025, attributed to net transfers between CDIs and common stock on the NYSE. Additionally, there was an increase in securities not issued as CDIs, driven by new share issues related to stock options, restricted stock units, and employee stock purchase plans, as well as share repurchases on the NYSE. This adjustment in securities reflects Resmed’s ongoing management of its capital structure and may impact its market positioning and stakeholder interests.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$47.04 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
ResMed Inc. has filed a notice for the proposed sale of securities under Rule 144, indicating that Brett Sandercock, an officer of the company, plans to sell 3,000 shares of common stock. The aggregate market value of these shares is approximately $742,620, with the sale expected to occur on November 3, 2025. This transaction follows a previous sale of 3,000 shares by Sandercock in September 2025, which yielded gross proceeds of $812,310. The announcement reflects ongoing insider trading activities and may impact stakeholder perceptions regarding the company’s stock performance.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$47.04 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
ResMed Inc. has filed its quarterly report for the period ending September 30, 2025, indicating compliance with the Securities Exchange Act of 1934. The report highlights the company’s financial performance and operational updates, providing stakeholders with insights into its market positioning and strategic initiatives. The filing confirms ResMed’s status as a large accelerated filer, reflecting its significant market presence and operational scale.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$51.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
ResMed Inc. has reported changes in the beneficial ownership of its securities, as disclosed in a recent filing. Brett Sandercock, the company’s Chief Financial Officer, executed transactions involving the acquisition and disposal of ResMed common stock under a pre-established Rule 10b5-1 trading plan. These transactions reflect ongoing strategic financial management and compliance with regulatory requirements, potentially impacting investor perceptions and market dynamics concerning ResMed’s stock.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$48.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
ResMed Inc’s Global General Counsel, Michael J. Rider, reported a transaction involving the disposal of 100 shares of ResMed common stock on October 1, 2025, at a price of $274.36 per share. This transaction was conducted under a pre-established Rule 10b5-1 trading plan, which allows company insiders to sell stocks at predetermined times to avoid accusations of insider trading. The transaction reflects a strategic financial decision by the company’s executive, potentially impacting the perception of the company’s stock value among stakeholders.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$48.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
ResMed Inc. announced an increase in the number of CHESS Depositary Interests (CDIs) issued over quoted securities, with a net addition of 3,066,120 CDIs in September 2025. This change is attributed to net transfers between CDIs and common stock, as well as activities related to stock options and employee stock plans. The company also reported a decrease in the number of securities over which CDIs have not been issued, due to share repurchases and new share issues on the NYSE.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$47.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
ResMed Inc. has announced its 2025 Annual Meeting, scheduled for November 19, 2025, in the US and November 20, 2025, in Australia. The meeting will be conducted virtually, allowing shareholders to participate and vote on various proposals. This announcement is significant as it emphasizes the company’s commitment to shareholder engagement and transparency, providing stakeholders with the opportunity to influence corporate governance and strategic decisions.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$47.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
Resmed Inc has filed a definitive proxy statement with the United States Securities and Exchange Commission, indicating no fee is required for this filing. This filing is part of the company’s compliance with the Securities Exchange Act of 1934, and it does not appear to have immediate implications for the company’s operations or stakeholders.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$47.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
Resmed Inc has filed a notice for the proposed sale of securities under Rule 144, with Brett Sandercock, an officer of the company, planning to sell 3,000 shares of common stock. The transaction, which involves securities acquired through restricted stock vesting and options granted, reflects a strategic decision by the officer, potentially impacting the company’s stock liquidity and market perception.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$47.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
Resmed Inc has announced a proposed sale of securities under Rule 144, involving the sale of 8,009 common shares by Michael J. Farrell, an officer and director of the company. The transaction, facilitated through Fidelity Brokerage Services LLC, is set to take place on September 8, 2025, with an aggregate market value of approximately $2,227,590.84. This sale follows previous transactions by Farrell within the past three months, reflecting a strategic decision that may impact the company’s stock liquidity and stakeholder interests.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$47.25 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
Resmed Inc announced a net decrease in the number of CHESS Depositary Interests (CDIs) issued over quoted securities for August 2025, with a reduction of 4,204,410 CDIs compared to the previous month. This change is attributed to net transfers between CDIs and common stock on the NYSE, as well as activities related to stock options, restricted stock units, employee stock purchase plans, and share repurchases. The announcement reflects the company’s ongoing management of its securities and may impact its market positioning and stakeholder interests.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$47.25 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
ResMed Inc has filed a notice of proposed sale of securities, indicating the sale of 3,000 common shares with an aggregate market value of $812,310. The shares are scheduled for sale on the NYSE on September 2, 2025. This transaction involves shares acquired through options granted in 2018 and restricted stock vesting in 2022, reflecting strategic financial management and potential liquidity adjustments by the company’s officer, Brett Sandercock.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$47.25 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
ResMed Inc.’s Chief Financial Officer, Brett Sandercock, reported a change in beneficial ownership with the acquisition of 5,462 shares of ResMed common stock on August 15, 2025. This transaction reflects the vesting of performance-based restricted stock units, indicating the company’s achievement of certain performance metrics, which may positively impact stakeholder confidence and demonstrate strong company performance.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$51.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
ResMed Inc reported a change in beneficial ownership as Director John Hernandez executed transactions involving the company’s common stock. On August 18, 2025, Hernandez acquired 2,575 shares through stock options at a price of $148.90 and subsequently sold the same amount at a weighted average price of $287.10, reflecting strategic financial management. These transactions indicate active engagement by the company’s leadership in managing their equity positions, potentially impacting investor perceptions and market dynamics.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$51.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
ResMed Inc announced a change in beneficial ownership involving its Global General Counsel, Michael J. Rider, who acquired 2,941 shares of ResMed common stock. This acquisition was part of a performance-based restricted stock unit plan, highlighting the company’s commitment to aligning executive compensation with performance metrics, which could positively impact stakeholder confidence in the company’s governance practices.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$51.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
ResMed Inc. has announced a change in beneficial ownership as reported in a recent SEC Form 4 filing. Michael J. Farrell, the Chief Executive Officer, acquired performance-based restricted stock units, which were granted in November 2024 and earned in August 2025 upon meeting performance metrics. This transaction highlights the company’s ongoing commitment to aligning executive compensation with performance, potentially impacting stakeholder confidence and company operations.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$51.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
Resmed Inc has filed a notice for the proposed sale of securities under Rule 144, involving 2,575 common shares with an aggregate market value of approximately $739,289.14. The sale is expected to take place on August 18, 2025, on the NYSE, with John Hernandez, a director of the company, as the account holder. This transaction reflects a routine financial activity and does not indicate any undisclosed adverse information about the company’s operations.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$41.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
ResMed Inc has announced an update regarding the foreign exchange rate for its upcoming dividend distribution to holders of CHESS Depositary Interests (CDIs) trading on the Australian Securities Exchange (ASX). The updated exchange rate is set at 0.6497 U.S. dollars for 1.00 Australian dollar, with a dividend of 0.0924 Australian dollars per CDI. The default U.S. withholding tax on dividends for Australian residents is 30%, but can be reduced to 15% under the U.S.-Australia tax treaty if the appropriate forms are submitted.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$41.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
ResMed Inc. has filed a notice for the proposed sale of securities under Rule 144, with Michael Farrell, an officer and director of the company, planning to sell 8,009 shares of common stock. The aggregate market value of these shares is approximately $2,265,185.47, and the sale is scheduled for August 7, 2025. This transaction follows previous sales by Farrell in May and June 2025, indicating a strategic move in managing personal investments, which may have implications for stakeholders regarding insider confidence and market perception.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$41.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
ResMed Inc.’s Chief Financial Officer, Brett Sandercock, reported changes in his beneficial ownership of the company’s common stock. On August 1, 2025, Sandercock acquired 2,000 shares through stock options and disposed of 3,000 shares, as part of a pre-established trading plan under Rule 10b5-1. These transactions reflect a routine adjustment in his holdings, with implications for his personal investment strategy rather than the company’s operational or market positioning.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$41.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
ResMed Inc. has reported a change in beneficial ownership as disclosed in a recent Form 4 filing. Michael J. Rider, the Global General Counsel, executed a transaction involving the sale of 50 shares of ResMed common stock at a price of $281.90 per share, under a Rule 10b5-1 plan adopted earlier in the year. This transaction reflects the company’s adherence to regulatory requirements and may have implications for its stock market performance and investor relations.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$41.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
Resmed Inc has announced an update on its CHESS Depositary Interests (CDIs), indicating a net increase of 278,240 CDIs issued over quoted securities in July 2025. This change is attributed to net transfers between CDIs and common stock, as well as activities related to stock options and employee stock plans. The update reflects the company’s ongoing adjustments in its securities management, which may impact its market positioning and stakeholder interests.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$41.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.